MedTrace Logo

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

NCT00670982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.

Conditions

Interventions

DRUG

bevacizumab

Given intravenously every 2 weeks

DRUG

vinorelbine

Given intravenously once a week

DRUG

trastuzumab

Given intravenously once a week

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • New Hampshire Oncology-Hematology PA

    collaborator UNKNOWN

  • Lowell General Hospital

    collaborator OTHER

  • Hartford Hospital

    collaborator OTHER

  • Harold J. Burstein, MD, PhD

    lead OTHER

Principal Investigators

  • Harold J. Burstein, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670982 on ClinicalTrials.gov